Alert

Recommended Alerts

Sign Up For Alerts

A new dawn for regulation of medical technologies in the UK post-Brexit? From European directives to the proposed stand-alone regulatory regime for the future

Last month the Medicines and Healthcare products Regulatory Agency launched a public consultation on the future of medical device regulation in the UK.

Read More

Proposed Legislation Would Authorize FDA To Approve Follow-on Biologics


Time to Read: 1 minutes Practices: Life Sciences Industries: Biotechnology & Pharmaceuticals

Printer-Friendly Version

The "Access to Life-Saving Medicine Act," introduced in late September, would authorize the Food and Drug Administration to approve follow-on biologics that closely resemble previously approved biological products. In its current version, the bill provides manufacturers of follow-on biologics with virtually everything they could ask for. The bill gives FDA substantial discretion to approve follow-on biologics and, in sharp contrast to the current legislative scheme governing drugs, the bill would not afford innovator companies any period of marketing exclusivity whatsoever for their biologic products. As a result, the manufacturers of previously approved biological products would be well-served to follow the forthcoming legislative debate on this issue very closely. For more on the bill and its various provisions, please click "Download PDF" to read Ropes & Gray's client alert.

Printer-Friendly Version

Cookie Settings